- Primary research
- Open Access
The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway
© Jia et al.; licensee BioMed Central Ltd. 2014
- Received: 13 June 2014
- Accepted: 10 November 2014
- Published: 30 November 2014
The mechanism underlying the differential cytotoxicity of curcumin in various cancer types, however, remains largely unclear. The aims of this study is to examine the concentration- and time-related effects of curcumin on two different breast cancer cells, MCF-7 and MDA-MB-231, and investigated the functional changes induced by curcumin treatment, as well as their relationship to the PI3K/Akt-SKP2-Cip/Kips pathway.
First, WST-1 and clonogenic assay were performed to determine the cytotoxicity of curcumin in MCF-7 and MDA-MB-231 cells. Then, the expression of CDK interacting protein/Kinase inhibitory protein (Cip/Kips) members (p27, p21 and p57) and S-phase kinase-associated protein-2 (SKP2) was investigated by QRT PCR and Western Blotting. Curcumin’s effect on PI3K (phosphatidylinositol 3-kinase) /Akt and its substrates Foxo1 and Foxo3a were then studied by Western Blotting. Small interfering RNAs (siRNAs) targeting SKP2 was used to explore the relationship between SKP2 and Cip/Kips members. Finally, WST-1 assay was tested to explore the concomitant treatment with curcumin and the inhibition of PKB or SKP2 signaling on curcumin sensitivity in MCF-7 and MDA-MB-231 cells.
We demonstrated MCF-7 and MDA-MB-231 cells exhibited differential responses to curcumin by WST-1 and clonogenic assay (MDA-MB-231 cells was sensitive, and MCF-7 cells was resistant), which were found to be related to the differential curcumin-mediated regulation of SKP2-Cip/Kips (p21 and p27 but not p57) signaling. The differential cellular responses were further linked to the converse effects of curcumin on PI3K/Akt and its substrates Foxo1 and Foxo3a. Importantly, PI3K inhibitor wortmannin could counteract both curcumin-induced phosphorylation of Akt and up-regulation of SKP2 in MCF-7 cells. Subsequent WST-1 assay demonstrated concomitant treatment with curcumin and wortmannin or SKP2 siRNA not only further augmented curcumin sensitivity in MDA-MB-231 cells but also overcame curcumin resistance in MCF-7 cells.
Our study established PI3K/Akt-SKP2-Cip/Kips signaling pathway is involved in the mechanism of action of curcumin and revealed that the discrepant modulation of this pathway by curcumin is responsible for the differential susceptibilities of these two cell types to curcumin.
- Curcumin sensitivity
- Breast cancer
Breast cancer remains the most common type of cancer in Asia. Despite displaying similar clinic pathological features, however, patients typically respond differently to therapies and display significantly different outcomes, indicating the substantial diversity of the various cancer subtypes. Indeed, genomic, epigenetic, transcriptional, and proteomic analyses have revealed that breast cancer subtypes may differ in pathway activity, progression, and response to therapy . Thus, a better understanding of the molecular mechanisms that impact patient response and resistance to candidate therapeutics may be helpful in predicting clinical response and developing more effective treatments for different subtypes of breast cancer.
Curcumin is a popular phytochemical that is used as a dietary additive. In Asia, dietary curcumin intake is very high; adults consume up to 200 mg, or 7-8 μmol/kg of body weight, per day . Curcumin has repeatedly been reported to be efficient and safe for the prevention and treatment of a wide spectrum of pathological conditions, including cancer ,. Mounting evidence suggests that the anti-tumor activity of curcumin may be attributed to its ability to induce apoptosis and arrest cell growth via pleiotropic mechanisms ,,. However, recent studies have also challenged the practice of dietary curcumin supplementation in cancer patients undergoing chemotherapy, including breast cancer patients ,, suggesting that it is necessary to first establish the benefit-risk profile of curcumin . Moreover, clinical trial data has indicated that patients respond differently to curcumin, which may be due to the differential molecular signaling that underlies distinct subtypes of cancer.
Considerable evidence exists demonstrating the roles of cell-cycle mediators in determining a cell’s fate toward proliferation, arrest, differentiation, quiescence, or apoptosis. The roles of members of the Cip/Kips family of cyclin-dependent kinase inhibitors (CDKi), such as p21 CIP1/WAF1/CDKN1A, p27 KIP2/CDKN1B, and p57 KIP2/CDKN1C, in negatively regulating the cell cycle and in genomic stability, apoptosis, senescence and DNA repair have been well characterized ,. Their functional changes may be associated with the differential susceptibilities of different cancer subtypes to anticancer drugs. However, the roles of members of the Cip/Kips family (p27, p21, and p57) in mediating cellular responses to curcumin in different subtypes of breast cancer cells remains widely unknown.
SKP2 is the specific substrate-recognition subunit of the SKP1 Cullin-F-box protein (SCF) type ubiquitin ligase complex. SKP2 has emerged as an important player in cell fate decisions by mediating the degradation of specific substrates, including members of the Cip/Kips family (p27, p57, and p21), p130, and c-Myc ,. SKP2 is considered to have strong independent prognostic potential and be a useful target for the treatment of breast cancer ,. SKP2 alterations have also been found to be key mediators that are involved in cancer growth and drug resistance -. Although the mechanisms that regulate SKP2 protein levels and how the protein differentially modulates the susceptibilities of different breast cancer cell types to chemotherapeutic drugs, such as curcumin, are not clearly understood, the PI3K/Akt survival pathway has been stated to be closely associated with the functions of SKP2. Lin et al. and Gao et al. reported that Akt-mediated phosphorylation of SKP2 at Ser-72 impaired its degradation and re-localized it to the cytosol, contributing to its oncogenic functions ,. In contrast, Boutonnet et al. and Bashir et al. reported that phosphorylation of SKP2 on Ser-72 did not control SKP2 binding to SKP1 and CUL1 and had no influence on SCFSKP2 ubiquitin ligase activity and its subcellular localization ,. Despite these conflicting reports, the results of these studies implied that activation of the PI3K/Akt pathway plays a positive role in stabilizing SKP2 and thereby promoting its oncogenic activities in regulating cell cycle progression, senescence and metastasis. Interestingly, the results of a recent study revealed that the SKP2 SCF complex was a critical E3 ligase for ErbB-receptor-mediated Akt ubiquitination, activation and membrane recruitment, and that SKP2 deficiency inhibited Akt activation and Glut1 expression, leading to repression of breast cancer development . These findings imply that a positive feedback loop composed of SKP2 and Akt promotes cancer cell progression through the restriction point. Furthermore, inhibition of the PI3K/Akt pathway by LY294002 was reported to result in p27 accumulation, which was associated with a decrease in SKP2 levels in MCF-7 cells . However, whether curcumin regulates SKP2 expression via this pathway in breast cancer remains unknown.
The present study aimed to seek the signaling pathway responsible for the differential susceptibilities of two different breast cancer cell lines, MCF-7 and MDA-MB-231, to the cytotoxic effects of curcumin. The concentration- and time-related roles of curcumin in modulating the distinct cellular responses of Cip/Kips proteins (p21, p27 and p57) and their upstream effectors, SKP2 and PI3K/Akt, were systematically examined. The interactions between these signaling molecules were further investigated in an effort to explain why MDA-MB-231 cells were sensitive, whereas MCF-7 cells were resistant, to curcumin treatment. The factors, such as SKP2 and Akt, that governed sensitivity to curcumin, especially in the curcumin-resistant MCF-7 cells, were subsequently evaluated. The results of the present study thus expanded our knowledge of the PI3K/Akt-SKP2-Cip/Kips pathway and highlighted the critical implication of this pathway in overcoming the drug (curcumin) resistance that is commonly observed in different subtypes of breast cancer.
The cytotoxicity of curcumin differs in MCF-7 and MDA-MB-231 cells
The clonogenic ability of MCF-7 and MDA-MB-231 cells differs following curcumin treatment
To further examine the cytotoxic effects of curcumin over a prolonged period of time, clonogenic assays were performed on both of the cell lines 7 or 12 days after treatment with 40 μM curcumin for 3 or 6 h, respectively. DNA analyses of the stained colonies revealed that curcumin treatment for both 3 and 6 h thoroughly abrogated the clonogenic ability of MDA-MB-231 cells (Figure 1B). In MCF-7 cells, however, the same concentration of curcumin did not significantly affect the capacity of the cells to form viable colonies after 3 h of treatment and only caused a slight decrease in the number of colonies after 6 h of treatment (Figure 1B). The results were consistent with the findings in the cell viability assays and further confirmed the differential responses of MCF-7 and MDA-MB-231 cells to curcumin.
The differential susceptibilities of MCF-7 andMDA-MB-231 cells to curcumin are associated with differential regulation of p27 and p21
Curcumin-induced down regulation of SKP2 protein and mRNA levels is involved in the induction of p27 and p21
Curcumin differentially affects the expression and activity of PKB and its substrates in MCF-7 and MDA-MB-231 cells
In parallel to SKP2, the effects of curcumin on the downstream targets of phospho-Akt, phospho-Foxo3a and phospho-Foxo1 in MCF-7 and MDA-MB-231 cells were also examined. As expected, continuous phosphorylation of Foxo1 at Thr-24 and Foxo3a at Ser-318/321 was observed in MCF-7 cells following curcumin treatment for 3, 6, 12, and 24 h, while in MDA-MB-231 cells, constitutive phosphorylation of Foxo3a and Foxo1 was inhibited by curcumin in a time-dependent manner (Figure 5C). These results suggested the participation of another Akt survival pathway by which MCF-7 cells escape cell death through phosphorylation of FKHR family transcription factors, thus conferring curcumin resistance.
Treatment with a PKB inhibitor and SKP2 siRNA sensitizes breast cancer cells to curcumin
Cip/Kips family proteins, such as p21 and p27, are well documented to function as both sensors and effectors of multiple anti-proliferative signals, and the absence of p21 and p27 has been linked to drug resistance in multiple human malignancies -. In breast cancer cells specifically, multi-phytochemical induced cytotoxicity has been revealed to be highly associated with p27 or p21 induction -. For instance, p21 and p27 are greatly enhanced following curcumin (50 μM) treatment for 3 h in MCF-7 cells . Chiu et al. also demonstrated that curcumin increased p21 independently of p53 in MDA-MB-231 cells . Similarly, while the results of our study demonstrated the effects of curcumin on p21 and p27 in MCF-7 and MDA-MB-231 cells, we further revealed, for the first time, that curcumin altered p27 and p21 in concentration- and time-related manners (Figure 2), which was in agreement with the differential response patterns of the two cell types to the cytotoxicity of curcumin (Figure 1). The curcumin-mediated functional changes in p21 and p27 may thus provide a molecular explanation as to why MCF-7 cells were resistant, while MDA-MB-231 cells were sensitive, to the cytotoxic effects of curcumin, which was also supported by recent findings indicating that the dual knockdown of the p21 and p27 genes lead to a significant suppression of MCF-7 cell proliferation. However, it is worth noting that our findings differed from an earlier report by Shao et al., in which treatment with higher concentrations of curcumin (up to 50 μM) for 72 h did not cause variations in p21, although multiple inhibitory effects were observed after curcumin (50 μM) treatment for 4 days in both MCF-7 and MDA-MB-231 cells . This discrepancy may be explained by the fact that the high curcumin concentration (50 μM) and prolonged treatment time (72 h) that was used in their study have resulted in extensive cell death.
Although we demonstrated in the present study that the distinct changes in p21 and p27 in MCF-7 and MDA-MB-231 cells may be linked to the differential susceptibilities of the cell lines to the effects of curcumin, the upstream signaling that affected p21 and p27 still remained elusive. Given that SKP2 plays critical roles in mediating the ubiquitin-dependent degradation of some cell-cycle proteins, including p27, p21 and p57 ,, and that aberrant SKP2 expression may contribute to the progression and development of a number of malignant tumors in humans, the effects of curcumin on SKP2 and the molecular relationship between these effects and the differential induction of p27 and p21 were further investigated in MCF-7 and MDA-MB-231 cells. We found that in the curcumin-sensitive MDA-MB-231 cells, curcumin significantly downregulated the expression of SKP2 at both the protein and transcriptional levels (Figures 3A and C). In the curcumin resistant MCF-7 cells, however, the suppression of SKP2 was only observed at higher concentrations (30 or 40 μM) and after a longer duration (12 or 24 h) of curcumin treatment (Figure 3B). In addition, a significant increase in SKP2 appeared following 3 or 6 h curcumin treatment (40 μM) (Figure 3B), indicating a deregulation of this protein in this cell line. Such distinct patterns of SKP2 in response to curcumin treatment were not only well correlated with the differential cytotoxicity but also with the alterations in p21 and p27 that were observed in MCF-7 and MDA-MB-231 cells, suggesting an interaction between SKP2 and p21/p27 that functionally governed the susceptibility of the two different cell types to curcumin. This interaction was further confirmed by the SKP2 siRNA assay, which revealed that SKP2 knockdown led to significant elevations in p21 and p27 expression in both MDA-MB-231 andMCF-7 cells (Figure 4), suggesting a mechanistic dependency of the curcumin-induced elevations of p21 and p27 on the suppression of SKP2. Previous studies have shown that antisense oligonucleotides against SKP2 mRNA inhibited the proliferation of cancer cell lines and increased the sensitivity of these cells to apoptotic stimuli ,. In particular, knockdown of SKP2 in MCF-7 cells inhibited cell growth and enhanced the cytotoxic effects of epirubicin . In addition, several studies revealed that the defective regulation of SKP2 was the key underlying cause of rapamycin resistance in multiple tumors and that SKP2 levels are a key determinant of antitumor responses to mTOR inhibitors . While in line with these observations, our findings further suggest that the differential susceptibilities to the cytotoxic effects of curcumin may be highly associated with the SKP2-Cip/Kips (p21 and p27) pathway, as observed in both cell lines, and that the deregulation of SKP2 and p21/p27 signaling may be responsible for curcumin resistance, as observed in MCF-7 cells. Furthermore, while a number of studies have focused on quantitative changes, such as the fact that the low levels of p27 in breast cancer cells were due to the high expression of SKP2 ,, very little attention has been paid to the relationship between p21 and p57 and SKP2-mediated degradation in breast cancer cells. The data from the present study further suggest a new possible mechanism underlying curcumin-induced changes in SKP2expression in MCF-7 and MDA-MB-231 cells that may be an important determinant ofp21 and p27 stability by reducing the rate of their SKP2-mediated degradation. In addition, no changes in p57 were observed in MCF-7 and MDA-MB-231 cells following curcumin treatment(Figure 2), regardless of SKP2 knockdown (data not shown), suggesting that the degradation of p57 in these cell lines may occur independently of SKP2, which differs from that observed in other types of tumors . Therefore, the extent of the functional dependency on SKP2 of different Cip/Kips proteins (p27, p21, and p57) in different breast cancer subtypes requires further study.
The constitutive or increased activity of the PI3K/Akt-dependent signaling cascade presents a major means by which cancer cells achieve uncontrolled proliferation, invasion, angiogenesis and drug resistance ,. Akt signaling has also been reported to play a critical role in SKP2 regulation in various cell types at both the transcriptional and post-translational levels ,,. To examine the interaction between Akt and SKP2, the phosphorylation status of Akt inMCF-7 and MDA-MB-231 cells after curcumin treatment was analyzed in this study. We demonstrated that in MDA-MB-231 cells curcumin could markedly inhibit the phosphorylation of Akt at Ser-473 in both a dose- and time-dependent manner (Figure 5A), which was in agreement with the changes that we observed in the expression pattern of SKP2 (Figures 3A and B), indicating that the inhibitory effects of curcumin on SKP2 may be highly related to the inhibitory role of curcumin in Akt activation. In MCF-7 cells, however, curcumin treatment caused a substantial increase in Akt phosphorylation, which exhibited a pattern that substantially differed from that of Akt in MDA-MB-231 cells (Figure 5A). Moreover, Akt phosphorylation at Ser-473 was unexpectedly observed to be maintained at high levels over the various curcumin concentrations or treatment times in MCF-7 cells (Figure 5A), which did not correspond to the curcumin-induced changes inSKP2 (Figures 3A and B). The present results demonstrated that curcumin treatment with either a lower concentration (10 or 20 μM) or a higher concentration (40 μM) for a shorter period of time (3 or 6 h) resulted in SKP2 up-regulation that could be attributed to Akt activation (Figures 3A, B and 5A). These results were confirmed by the co-administration of curcumin with the selective PI3K inhibitor, wortmannin, which reversed the phosphorylation of Akt and the up-regulation of SKP2 in MCF-7 cells (Figure 5B). In contrast, when a higher concentration of curcumin (30 or 40 μM) was used, the resulting up-regulationof SKP2didnot occur in response to the elevated Akt phosphorylation (Figures 3A, B and 5A), implying the involvement of another curcumin-targeted signaling pathway, rather than merely Akt, which predominantly modulates SKP2 expression. Indeed, recent evidence has indicated a critical role of Focal Adhesion Kinase (FAK) in the regulation of Cip/Kips through SKP2-dependent and SKP2-independent mechanisms ,. Whether the FAK-associated pathway is a direct target of curcumin requires further investigation. With regard to the interaction between Akt and SKP2 in breast cancer cell lines, several previous studies have obtained data that were similar to our results, in which the treatment of MCF-7 cells with inhibitor of PI3K (LY294002) was shown to significantly decrease the expression of SKP2 , and the use of rapamycin, an mTOR inhibitor, induced cytotoxicity via the suppression of SKP2 in MDA-MB-231 cells . The present study further explored the idea that the distinct behavior of the PI3K/Akt-SKP2 signaling pathway in response to curcumin was highly associated with the differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin, in which the levels of Akt phosphorylation was an important factor influencing its ability to determine the activity of SKP2 and thereby affected the responses of the breast cancer cells to curcumin. This notion was validated by the results of the WST-1 assay, which indicated that the use of a PI3K inhibitor (wortmannin) or the down-regulation of SKP2 (SKP2 siRNA) not only augmented the sensitivity of the curcumin-sensitive MDA-MB-231 cells, but more impressively, also significantly enhanced the response of the curcumin-resistant MCF-7 cells to curcumin treatment compared to curcumin alone (Figure 6). Despite the fact that the exact mechanism underlying the curcumin-mediated regulation of SKP2 is not fully understood, the present study illuminated the fact that the PI3K/Akt-SKP2 pathway functioned differentially in response to curcumin in the two breast cancer subtypes and that the ability of curcumin to inactivate SKP2-dependent signaling was impaired by the continuous Akt phosphorylation in the curcumin-resistant MCF-7 cells, suggesting that the co-administration of curcumin and PI3K- and/ or SKP2-targeted inhibitors may be better alternatives in clinical practice.
In addition to SKP2, the FKHR family transcription factors (FOXO) have also been reported to be downstream targets of Akt that mediate apoptosis in breast cancer . FOXO activation promoted the transcription of genes involved in cell cycle arrest and apoptosis . One mechanism by which Akt promotes cell survival is via FOXO phosphorylation, which inactivates FOXO and prevents apoptosis ,. Interestingly, we also found that both Foxo1 and Foxo3a responded in different manners to curcumin treatment in MCF-7 and MDA-MB-231 cells. Curcumin treatment caused Foxo1 and Foxo3a dephosphorylation in MDA-MB-231 cells, while Foxo1 and Foxo3a continued to be phosphorylated in MCF-7 cells (Figure 5C). Notably, the patterns of Foxo1 and Foxo3a changes that were brought about by curcumin treatment were in agreement with those observed for p-Akt in MCF-7 and MDA-MB-231 cells, suggesting that another Akt survival pathway modulated the phosphorylation status of FOXO, which may also explain why MDA-MB-231 cells were sensitive to curcumin treatment, while MCF-7 cells were resistant.
Our study established the importance of the PI3K/Akt-SKP2-Cip/Kips signaling pathway and revealed that the discrepant modulation of this pathway by curcumin was highly responsible for the differential susceptibilities of these two cell types to curcumin. Accordingly, the results of the present study further suggested that p-Akt and SKP2 are both important pharmacogenomic markers that can be used to predict the sensitivity of breast cancer cells to curcumin and that SKP2 silencing and p-Akt inhibition may be potent therapeutic alternatives that can be used in combination with curcumin to treat different breast cancer subtypes.
Chemicals and reagents
Curcumin, with a purity ≥95%, was obtained from Unilever R&D (Sanjivani Phytopharma Pvt. Ltd, India). Wortmannin and dimethyl sulfoxide (DMSO) were purchased from Sigma Chemical Co. (St. Louis, MO). DMEM GlutaMAX medium containing L-Glutamine, and Leibovitz’s L-15 medium containing L-Glutamine and 0.05% Trypsin-EDTA, were obtained from Gibco BRL (Grand Island, NY, USA). FBS was obtained from PAA (Coelbe, Germany). Antibodies that had been raised against S-phase kinase associated protein 2 (SKP2), p27 Kip1, p21 Waf1/Cip1, phospho-Foxo1 (Thr-24), p-Foxo3a (Ser-318/321), β-actin, GAPDH and an anti-rabbit IgG antibody linked with HRP were purchased from Cell Signaling Technology (Beverly, MA). Antibodies that had been raised against Akt and p57 were obtained from Bioworld (China). An antibody that had been raised against p-Akt Ser-473 was obtained from Abcam (Cambridge, UK).
Cell culture and curcumin treatment
MCF-7 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD). MDA-MB-231 cells were purchased from Cell Bank of the Chinese Academy of Sciences (Shanghai, China), where the cells were characterized by mycoplasma detection, DNA –Fingerprinting, isoenzyme analysisand cell vitality detection. All these cells were maintained in American Type Culture Collection recommended cell culture media andconditions. MCF-7 cells were grown in DMEM medium containing 10% (V/V) FBS without antibiotics at 37°C in a humidified atmosphere containing 95% air and 5% CO2. MDA-MB-231 cells were grown in L-15 medium containing 10% (V/V) FBS without antibiotics at 37°C. Curcumin was dissolved in DMSO to a stock concentration of 20 mM in a dark colored bottle at −20°C and was diluted to the required concentration with medium when needed. Prior to curcumin treatment, the cells were grown to a density of approximately 80% and were then treated with curcumin at different concentrations for the indicated times. The control cells were incubated with DMSO at the same final concentration.
Cell viability assay
Cell viability was determined in vitro using the water-soluble tetrazolium WST-1 assay (Roche Molecular Biochemicals, Mannheim, Germany). The cells were seeded at a density of 10,000 cells/ well in 96 well plates and cultured overnight. The cells were then treated with curcumin at various concentrations (2, 4, 6, 8, 10, 20, 30, and 40 μM) for 12 and 24 hours. Cells that were incubated with an equivalent amount of DMSO without curcumin served as controls. After the treatments, the medium was aspirated and the cells were washed with PBS. Then, 10 μl of WST-1 reagent was added to each well. The plates were mixed gently and the cells were incubated for 2 to 4 hours. After the incubation period, the plates were mixed gently on an orbital shaker for one minute and the absorbance of each sample was measured at 430 nm using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA).
The breast cancer cells were plated in six-well plates overnight and treated with 40 μM curcumin for a period of 3 or 6 h. After the removal of the drug-containing medium, the cells were washed using PBS, trypsinized and plated at a low density (2000 cells/ well in six-well plates). The cells were then incubated with an equivalent amount of DMSO without curcumin, which served as a control. The cells were cultivated for 7 or 12d and the medium was refreshed every two days. The colonies were stained with crystal violet (Sigma Chemical Co, St. Louis, MO). The number of clones in a given area was counted for each condition.
Quantitative real-time reverse transcription-PCR
Total RNA was extracted using Trizol reagent (Invitrogen, USA). Two micrograms of RNA was reverse transcribed using the Reverse Transcription System (Promega, USA), according to the manufacturer’s recommended instructions. The cDNA was diluted ten-fold prior to PCR amplification. Real-time PCR was performed using a FastSYBR Mixture (CWBIO, China). The primer pairs that were used were as follows: SKP2, (forward) 5′-GCTGCTAAAGGTCTCTGGTGT-3′, (reverse) 5′- AGGCTTAGATTCTGCAACTTG-3′; and GAPDH, which served as an internal control, (forward) 5′-TCTCTGCTCCTCCTGTTC-3′ and (reverse) 5′-CTCCTGGAAGATGGTGATG-3′. The mRNA levels of SKP2 were quantified by measuring the threshold cycle (Ct).
The cells were treated as described in the figure legends. After the treatments, the cells were placed on ice, washed with cold PBS and lysed in RIPA lysis buffer (Beyotime, China) that had been supplemented with 1 mM PMSF, a protease inhibitor cocktail and a phosphatase inhibitor cocktail (KangChen, China). Cell lysates were centrifuged at 14,000 × g at 4°C for 5 mins. Protein concentrations were determined using a BCA kit (Beyotime, China). Approximately 40–50 μg of cellular protein from each sample was loaded onto 8% or 12% SDS-polyacrylamide gels and electrotransferred to nitrocellulose (NC) membranes (0.22/0.45 μm) (Millipore Billerica, USA). The blotted membranes were incubated with different primary antibodies, followed by incubations with secondary antibodies. The proteins were visualized using an ECL kit (Millipore, Billerica, USA). Relative protein levels were normalized to β-actin/GAPDH. A Quantity One Gel Doc XR gel imaging system (Bio-Rad, USA) was used for the detection and analysis of band intensity.
Specific RNA-mediated SKP2 down-regulation
Small interfering RNAs (siRNAs) targeting SKP2 were purchased from Qiagen. For transient expression, the cell lines were transfected using HiPerFect Transfection Reagent (Qiagen), as outlined in the HiPerFect Transfection Reagent Handbook (Fifth edition, Qiagen). AllStars Negative siRNA AF 488 (Qiagen) was used both as a negative control and to determine the transfection efficiency. Two independent experiments were performed. SKP2 siRNA data: the target sequence is 5′-AAGTGATAGTCATGCTAAA-3′, the sense strand is 5′-GUGAUAGUGUCAUGCUAAATT-3′ and the antisense strand is 5′-UUUAGCAUGACACUAUCACTT-3′.
The values were expressed as the means ± SD. The statistical significance of the mean values among the different cell lines was determined using one-way ANOVA, followed by Student’s t test.
We thank Dr. Jean–Luc Coll (INSERM U823, France) for critical review of the manuscript. We thank Zitao Guo (Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China) for excellent technical assistance.
The work was partially supported by grants from the National Natural Science Foundation of China [No. 31171019 (Z. Zhao) and No. 31200820 (Y. Duan)], and the Opening Project of Shanghai Key Laboratory of Brain Functional Genomics and Key Laboratory of Brain Functional Genomics (East China Normal University), Ministry of Education (J. Zhang).
- Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA: Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A. 2012, 109: 2724-2729. 10.1073/pnas.1018854108.View ArticlePubMed CentralPubMedGoogle Scholar
- Commandeur JN, Vermeulen NP: Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin. Xenobiotica. 1996, 26: 667-680. 10.3109/00498259609046741.View ArticlePubMedGoogle Scholar
- Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008, 52 (Suppl 1): S103-S127.PubMedGoogle Scholar
- Goel A, Kunnumakkara AB, Aggarwal BB: Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol. 2008, 75: 787-809. 10.1016/j.bcp.2007.08.016.View ArticlePubMedGoogle Scholar
- Mehta K, Pantazis P, McQueen T, Aggarwal BB: Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs. 1997, 8: 470-481. 10.1097/00001813-199706000-00010.View ArticlePubMedGoogle Scholar
- Teiten MH, Eifes S, Dicato M, Diederich M: Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel). 2010, 2: 128-162. 10.3390/toxins2010128.View ArticleGoogle Scholar
- Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ: Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002, 62: 3868-3875.PubMedGoogle Scholar
- Burgos-Moron E, Calderon-Montano JM, Salvador J, Robles A, Lopez-Lazaro M: The dark side of curcumin. Int J Cancer. 2010, 126: 1771-1775.PubMedGoogle Scholar
- Russo M, Spagnuolo C, Tedesco I, Russo GL: Phytochemicals in cancer prevention and therapy: truth or dare?. Toxins (Basel). 2010, 2: 517-551. 10.3390/toxins2040517.View ArticleGoogle Scholar
- Denicourt C, Dowdy SF: Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev. 2004, 18: 851-855. 10.1101/gad.1205304.View ArticlePubMedGoogle Scholar
- Lim S, Kaldis P: Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013, 140: 3079-3093. 10.1242/dev.091744.View ArticlePubMedGoogle Scholar
- Sun Y: Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther. 2003, 2: 623-629.PubMedGoogle Scholar
- Nakayama KI, Nakayama K: Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol. 2005, 16: 323-333. 10.1016/j.semcdb.2005.02.010.View ArticlePubMedGoogle Scholar
- Traub F, Mengel M, Luck HJ, Kreipe HH, von Wasielewski R: Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat. 2006, 99: 185-191. 10.1007/s10549-006-9202-3.View ArticlePubMedGoogle Scholar
- Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M: Significance of skp2 expression in primary breast cancer. Clin Cancer Res. 2006, 12: 1215-1220. 10.1158/1078-0432.CCR-05-1709.View ArticlePubMedGoogle Scholar
- Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, Sarkar FH, Wei W: Skp2 is a promising therapeutic target in breast cancer. Front Oncol. 2012, 1: 18702-18712. 10.3389/fonc.2011.00057.View ArticlePubMedGoogle Scholar
- Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK: Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013, 154: 556-568. 10.1016/j.cell.2013.06.048.View ArticlePubMedGoogle Scholar
- Hershko DD: Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer. 2008, 112: 1415-1424. 10.1002/cncr.23317.View ArticlePubMedGoogle Scholar
- Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, Tempst P, Pandolfi PP: Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009, 11: 420-432. 10.1038/ncb1849.View ArticlePubMed CentralPubMedGoogle Scholar
- Gao DM, Inuzuka H, Tseng A, Chin RY, Toker A, Wei WY: Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APC-Cdh1-mediated Skp2 destruction. Nat Cell Biol. 2009, 11: 397-408. 10.1038/ncb1847.View ArticlePubMed CentralPubMedGoogle Scholar
- Bashir T, Pagan JK, Busino L, Pagano M: Phosphorylation of Ser72 is dispensable for Skp2 assembly into an active SCF ubiquitin ligase and its subcellular localization. Cell Cycle. 2010, 9: 971-974. 10.4161/cc.9.5.10914.View ArticlePubMed CentralPubMedGoogle Scholar
- Boutonnet C, Tanguay PL, Julien C, Rodier G, Coulombe P, Meloche S: Phosphorylation of Ser72 does not regulate the ubiquitin ligase activity and subcellular localization of Skp2. Cell Cycle. 2010, 9: 975-979. 10.4161/cc.9.5.10915.View ArticlePubMedGoogle Scholar
- Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, Nakayama KI, Lin HK: The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis. Cell. 2012, 149: 1098-1111. 10.1016/j.cell.2012.02.065.View ArticlePubMed CentralPubMedGoogle Scholar
- Huang HC, Way TD, Lin CL, Lin JK: EGCG Stabilizes p27(kip1) in E2-Stimulated MCF-7 Cells through Down-Regulation of the Skp2 Protein. Endocrinology. 2008, 149: 5972-5983. 10.1210/en.2008-0408.View ArticlePubMedGoogle Scholar
- Dillon RL, Muller WJ: Distinct biological roles for the akt family in mammary tumor progression. Cancer Res. 2010, 70: 4260-4264. 10.1158/0008-5472.CAN-10-0266.View ArticlePubMed CentralPubMedGoogle Scholar
- Ecker K, Hengst L: Skp2: caught in the Akt. Nat Cell Biol. 2009, 11: 377-379. 10.1038/ncb0409-377.View ArticlePubMedGoogle Scholar
- Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM: Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A. 2000, 97: 9042-9046. 10.1073/pnas.160016897.View ArticlePubMed CentralPubMedGoogle Scholar
- Tchernev G, Orfanos CE: Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. J Cutan Pathol. 2007, 34: 247-256. 10.1111/j.1600-0560.2006.00700.x.View ArticlePubMedGoogle Scholar
- Schmidt M, Fan Z: Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells. Oncogene. 2001, 20: 6164-6171. 10.1038/sj.onc.1204814.View ArticlePubMedGoogle Scholar
- Shrotriya S, Deep G, Ramasamy K, Raina K, Barbakadze V, Merlani M, Gogilashvili L, Amiranashvili L, Mulkijanyan K, Papadopoulos K, Agarwal C, Agarwal R: Poly[3-(3, 4-dihydroxyphenyl) glyceric] acid from Comfrey exerts anti-cancer efficacy against human prostate cancer via targeting androgen receptor, cell cycle arrest and apoptosis. Carcinogenesis. 2012, 33: 1572-1580. 10.1093/carcin/bgs019.View ArticlePubMedGoogle Scholar
- Vaid M, Sharma SD, Katiyar SK: Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation. Carcinogenesis. 2010, 31: 2004-2011. 10.1093/carcin/bgq186.View ArticlePubMedGoogle Scholar
- Kim KC, Lee C: Curcumin induces downregulation of E2F4 expression and apoptotic cell death in HCT116 human colon cancer cells; involvement of reactive oxygen species. Korean J Physiol Pharmacol. 2010, 14: 391-397. 10.4196/kjpp.2010.14.6.391.View ArticlePubMed CentralPubMedGoogle Scholar
- Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G: Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharm. 2007, 73: 1024-1032. 10.1016/j.bcp.2006.12.010.View ArticlePubMedGoogle Scholar
- Chiu TL, Su CC: Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappa Bp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med. 2009, 23: 469-475.PubMedGoogle Scholar
- Shao ZM, Shen ZZ, Liu CH, Sartippour MR, Go VL, Heber D, Nguyen M: Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer. 2002, 98: 234-240. 10.1002/ijc.10183.View ArticlePubMedGoogle Scholar
- Harada K, Supriatno , Kawashima Y, Itashiki Y, Yoshida H, Sato M: Down-regulation of S-phase kinase associated protein 2 (Skp2) induces apoptosis in oral cancer cells. Oral Oncol. 2005, 41: 623-630. 10.1016/j.oraloncology.2005.02.007.View ArticlePubMedGoogle Scholar
- Yokoi S, Yasui K, Iizasa T, Takahashi T, Fujisawa T, Inazawa J: Down-regulation of SKP2 induces apoptosis in lung-cancer cells. Cancer Sci. 2003, 94: 344-349. 10.1111/j.1349-7006.2003.tb01444.x.View ArticlePubMedGoogle Scholar
- Sun L, Cai L, Yu Y, Meng Q, Cheng X, Zhao Y, Sui G, Zhang F: Knockdown of S-phase kinase-associated protein-2 expression in MCF-7 inhibits cell growth and enhances the cytotoxic effects of epirubicin. Acta Biochim Biophys Sin (Shanghai). 2007, 39: 999-1007. 10.1111/j.1745-7270.2007.00361.x.View ArticleGoogle Scholar
- Totary-Jain H, Sanoudou D, Dautriche CN, Schneller H, Zambrana L, Marks AR: Rapamycin resistance is linked to defective regulation of Skp2. Cancer Res. 2012, 72: 1836-1843. 10.1158/0008-5472.CAN-11-2195.View ArticlePubMed CentralPubMedGoogle Scholar
- Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M: Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002, 110: 633-641. 10.1172/JCI0215795.View ArticlePubMed CentralPubMedGoogle Scholar
- Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, Hatakeyama S, Nakayama K, Nakayama KI: Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A. 2003, 100: 10231-10236. 10.1073/pnas.1831009100.View ArticlePubMed CentralPubMedGoogle Scholar
- Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog. 2012, 17: 69-95. 10.1615/CritRevOncog.v17.i1.60.View ArticlePubMedGoogle Scholar
- Liang J, Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003, 2: 339-345. 10.4161/cc.2.4.433.View ArticlePubMedGoogle Scholar
- Cox BD, Natarajan M, Stettner MR, Gladson CL: New concepts regarding focal promotion of cell migration adhesion kinase and proliferation. J Cell Biochem. 2006, 99: 36-52. 10.1002/jcb.20956.View ArticleGoogle Scholar
- Bryant P, Zheng Q, Pumiglia K: Focal adhesion kinase controls cellular levels of p27/Kip1 and p21/Cip1 through Skp2-dependent and -independent mechanisms. Mol Cell Biol. 2006, 26: 4201-4213. 10.1128/MCB.01612-05.View ArticlePubMed CentralPubMedGoogle Scholar
- Shapira M, Kakiashvili E, Rosenberg T, Hershko DD: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res. 2006, 8: R46-10.1186/bcr1533.View ArticlePubMed CentralPubMedGoogle Scholar
- Reagan-Shaw S, Ahmad N: RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. Cancer Res. 2006, 66: 1062-1069. 10.1158/0008-5472.CAN-05-1018.View ArticlePubMedGoogle Scholar
- Reagan-Shaw S, Ahmad N: The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol Appl Pharmacol. 2007, 224: 360-368. 10.1016/j.taap.2006.12.003.View ArticlePubMedGoogle Scholar
- Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME: Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol. 2001, 21: 952-965. 10.1128/MCB.21.3.952-965.2001.View ArticlePubMed CentralPubMedGoogle Scholar
- Wu YY, Shang XY, Sarkissyan M, Slamon D, Vadgama JV: FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 2010, 70: 5475-5485. 10.1158/0008-5472.CAN-10-0176.View ArticlePubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.